Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Bobby Chi-Hung Liaw"'
Autor:
Jacqueline R. Griffin, Tomi Jun, Sunny Guin, Bobby Chi-Hung Liaw, Vaibhav G. Patel, Che-Kai Tsao, Michael R. Rossi, Rong Chen, Xiang Zhou, Feras Hantash, William K. Oh
Publikováno v:
Journal of Urology. 207
Autor:
Qian Qin, Nicole J. Zubizarreta, Matt D. Galsky, Bobby Chi-Hung Liaw, Vaibhav G. Patel, John P. Sfakianos, Reza Mehrazin, Michael Palese, Ketan Badani, Nikhil Waingankar, Rachel Brody, Nina Bhardwaj, Amish Doshi, William L Simpson, David F Yankelevitz, Amir Horowitz, Kai Tsao
Publikováno v:
Journal of Clinical Oncology. 41:TPS751-TPS751
TPS751 Background: Five doublet combinations incorporating immune checkpoint inhibitor (ICI) with or without tyrosine kinase inhibitor (TKI) are now approved for the first line treatment (tx) of advanced ccRCC. In COSMIC-313, the triplet combination
Autor:
Zakaria Chakrani, George Slade Mellgard, Stephen Mccroskery, Nathaniel Saffran, Nicole Taylor, Bobby Chi-Hung Liaw, William K. Oh, Kai Tsao, Vaibhav G. Patel
Publikováno v:
Journal of Clinical Oncology. 41:135-135
135 Background: mCRPC is associated with (a/w) increased mortality among prostate cancer pts and new and safe txs are needed. In recent clinical trials, ARTs improved survival outcomes within this population, however, a significant portion will go on
Autor:
George Slade Mellgard, Stephen Mccroskery, Zakaria Chakrani, Nathaniel Saffran, Nicole Taylor, Bobby Chi-Hung Liaw, Matt D. Galsky, William K. Oh, Kai Tsao, Vaibhav G. Patel
Publikováno v:
Journal of Clinical Oncology. 41:118-118
118 Background: mCRPC pts with significant comorbidities or poor performance status (PS) are often excluded from clinical trials for ART. These cohorts may not be representative of or comparable to real-world pts. We aimed to determine whether (1) ba
Autor:
George Slade Mellgard, Nathaniel Saffran, Zakaria Chakrani, Stephen Mccroskery, Nicole Taylor, Bobby Chi-Hung Liaw, Matt D. Galsky, Kai Tsao, Vaibhav G. Patel
Publikováno v:
Journal of Clinical Oncology. 41:194-194
194 Background: Statins may reinforce and provide a compounded effect on ART by decreasing cholesterol levels thus decreasing de novo androgen synthesis. We aim to investigate the clinical effect of concurrent statin and ART use on outcomes of mCRPC
Publikováno v:
Journal of Clinical Oncology. 40:4532-4532
4532 Background: Multiple regimens incorporating tyrosine kinase inhibitors (TKI) or immune checkpoint inhibitors (ICI), either alone or in combination, confer a significant OS benefit in 1L metastatic clear cell RCC. However, guidance for optimal tr
Autor:
Jacqueline R. Griffin, Tomi Jun, Bobby Chi-Hung Liaw, Sunny Guin, Che-Kai Tsao, Vaibhav G. Patel, Michael Rossi, Xiang Zhou, Feras Hantash, Rong Chen, William K. Oh
Publikováno v:
Journal of Clinical Oncology. 40:112-112
112 Background: Next-generation sequencing (NGS) is increasingly common in clinical practice, but its clinical utility may depend on the availability of sequencing-directed therapies (SDT). There were no FDA-approved SDTs in prostate cancer (PCa) unt
Autor:
Xiaobo Zhong, Vaibhav G. Patel, Che-Kai Tsao, Bobby Chi-Hung Liaw, Matthew D. Galsky, Douglas Tremblay, William Oh
Publikováno v:
Annals of Oncology
Background Cell entry of SARS-CoV-2 depends on binding of the viral spike (S) proteins to ACE2 and on S protein priming by TMPRSS2. Inhibition of TMPRSS2 may work to block or decrease the severity of SARS-CoV-2 infections. Intriguingly, TMPRSS2 is an
Autor:
Xiang Zhou, Marc Y. Fink, Bobby Chi-Hung Liaw, Scott Newman, Kristin L. Ayers, Michael I. Klein, Sunny Guin, Eric E. Schadt, Bonny Patel, William Oh, Matthew Dietz, Tony Prentice, Rong Chen, Timmy O’Connell, Tomi Jun
Publikováno v:
Journal of Clinical Oncology. 39:e17047-e17047
e17047 Background: The addition of docetaxel or a novel hormonal agent (NHA), such as abiraterone acetate or enzalutamide, has become standard of care for mHSPC, but prospective data for comparative efficacy remains limited. Clinical variables abstra
Publikováno v:
Nature Reviews Clinical Oncology. 14:269-283
The increasing potency of therapies that target the androgen receptor (AR) signalling axis has correlated with a rise in the proportion of patients with prostate cancer harbouring an adaptive phenotype, termed treatment-induced lineage crisis. This p